Role of adiponectin and adipocyte fatty acid binding protein in the metabolic syndrome

Diabetes Research and Clinical Practice

Volumn 77, Issue 3 SUPPL., 2007, Pages

  Maeda, Kazuhisa ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adiponectin; aP2; Japanese Human Genome Project; Metabolic syndrome

Indexed keywords

ACYL COENZYME A DESATURASE; ADIPONECTIN; APOLIPOPROTEIN E; CCAAT ENHANCER BINDING PROTEIN; CD36 ANTIGEN; FATTY ACID BINDING PROTEIN; LEPTIN; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; C57BL 6 MOUSE; ENERGY METABOLISM; ETHNIC GROUP; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN GENOME PROJECT; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; LIPID TRANSPORT; METABOLIC SYNDROME X; NONHUMAN; NORTHERN BLOTTING; PIMA INDIAN;

ADIPOCYTES; ADIPONECTIN; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; METABOLIC SYNDROME X;

EID: 34547683527     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.028     Document Type: Article

References (23)

1. Maeda K., Okubo K., Shimomura I., Mizuno K., Matsuzawa Y., and Matsubara K. Analysis of an expression profile of genes in the human adipose tissue. Gene 190 (1997) 227-235
2. Okubo K., Hori N., Matoba R., Niiyama T., Fukushima A., Kojima Y., et al. Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat. Genet. 2 (1992) 173-179
3. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript-1). Biochem. Biophys. Res. Commun. 221 (1996) 286-289
4. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
5. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1595-1599
6. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
7. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 85-89
8. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., and Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274 (1996) 1377-1379
9. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270 (1995) 26746-26749
10. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271 (1996) 10697-10703
11. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
12. Zoccali C., Mallamaci F., Tripepi G., Benedetto F.A., Cutrupi S., Parlongo S., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 13 (2002) 134-141
13. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
14. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 29-33
15. Bernlohr D.A., Coe N.R., and LiCata V.J. Fatty acid trafficking in the adipocyte. Semin. Cell. Dev. Biol. 10 (1999) 43-49
16. Uysal K.T., Scheja L., Wiesbrock S.M., Bonner-Weir S., and Hotamisligil G.S. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141 (2000) 3388-3396
17. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., and Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 280 (2005) 12888-12895
18. Makowski L., Boord J.B., Maeda K., Babaev V.R., Uysal K.T., Morgan M.A., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7 (2001) 699-705
19. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell. Metab. 1 (2005) 107-119
20. Tuncman G., Erbay E., Hom X., De Vivo I., Campos H., Rimm E.B., et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 6970-6975
21. Cao H., Maeda K., Gorgun C., Kim H., Park S., Shulman G., et al. Regulation of metabolic responses by adipocyte/macrophage fatty acid binding proteins in leptin-deficient mice. Diabetes 55 (2006) 1915-1922
22. Kubota N., Terauchi Y., Kubota T., Kumagai H., Itoh S., Satoh H., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem. 281 (2006) 8748-8755
23. Maeda K., Atsumi G., Maeda N., Yamamoto K., Kihara S., Funahashi T., et al. Thiazolidinediones protects the early development of atherosclerosis adiponectin-dependently in apoE deficient background. Obes. Res. 38 (2006) 29